BioMarin announces five-year Phase 3 data for Pombiliti, Opfolda
BioMarin said it will present five-year Phase 3 data for Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) at the World Muscle Society Annual Congress.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.